Hotline 24/7: 0909384389

Share links:

Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders

Ngày 12/06/2019 03:55 | Lượt xem: 3866

Thrombolex has announced that the US Food and Drug Administration (FDA) has cleared the Bashir Endovascular Catheter (BEC) for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, and the Bashir N-X Endovascular Catheter (BEC N-X) for the controlled and selective infusion of physician-specified fluids into the peripheral and pulmonary artery vasculature.

Thrombolex has announced that the US Food and Drug Administration (FDA) has cleared the Bashir Endovascular Catheter (BEC) for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, and the Bashir N-X Endovascular Catheter (BEC N-X) for the controlled and selective infusion of physician-specified fluids into the peripheral and pulmonary artery vasculature. The company has also received FDA clearance to begin an early feasibility study evaluating the Bashir platform for treatment of pulmonary embolism. 

The BEC is the only pharmacomechanical catheter cleared by the FDA that incorporates a physician controlled distal segment with six expandable mini-infusion catheters to deliver physician specified fluids in precise locations in the patient’s peripheral vasculature.

Riyaz Bashir, professor of Medicine, Director of Vascular and Endovascular Medicine at Temple University Hospital (Philadelphia, USA) said, “My inspiration for the BEC platform technology was to develop a device that I hoped would provide better treatment outcomes by rapid restoration of blood flow through the thrombus thereby enhancing both endogenous and exogenous fibrinolysis.” Bashir went on to say, “acute venous thromboembolic (VTE) disease has become a significant public health concern in the USA, with approximately 900,000 patients diagnosed and causing up to 100,000 deaths each year.”

Marvin Woodall, Chairman & CEO and co-founder of Thrombolex said, “Our dedicated team is proud to have received FDA clearance for our first two catheter-directed thrombolysis (CDT) products to treat patients suffering from acute VTE disorders”. Michael Cerminaro, president, COO and co-founder of Thrombolex commented, “Our first two products feature unique platform technologies which will be included in our significant pipe-line of new products currently being developed.”

Brian Firth, chief scientific officer of Thrombolex, said, “We recently received FDA clearance to begin an Early Feasibility Study (EFS) to demonstrate the safety and feasibility of the Bashir platform technology in the treatment of acute pulmonary embolism (PE). The protocol requires the use of the BECs expandable mini-infusion catheters to deliver low-doses of r-tPA directly into an acute PE.” Firth further stated, “The goal is to minimises the risk of major bleeding complications (including intracranial haemorrhage) associated with systemic lytic administration.”

Further clinical data will provide new insights into the advantages of rapid restoration of blood flow. Thrombolex believe that harnessing the endogenous lytics in the patient’s own blood in a synergistic manner with a lower dose of exogenous lytic has the potential to accelerate clot lysis and more effectively reduce the total thrombus burden. This should reduce the incidence of chronic pulmonary thromboembolic disease and post thrombotic syndrome.

The BEC and the BEC N-X are currently only available in the USA. Plans for distribution outside the USA are forthcoming. Thrombolex representatives will be present at the Society for Cardiovascular Angiography & Interventions (SCAI) Conference in Las Vegas on May 20-22, 2019 and invite physicians to visit their exhibit for additional information.

Source venous.new

Duc Tin Clinic

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

CUSTOMER REVIEWS

• I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

  I sincerely thank you !. Tel: 0938303275

• Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

  Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

• As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

• The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

• I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search

News

Customer support